We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-23.36%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$232M
AUM Growth
-$50.4M
Cap. Flow
+$36.6M
Cap. Flow %
15.81%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$37.6M

Top Sells

Rank Stock Value
1
ELEV
Elevation Oncology
ELEV
+$986K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.48B
$80.6M 34.83%
4,289,304
– –
ALXO icon
2
ALX Oncology
ALXO
$277M
$58.5M 25.26%
9,699,925
– –
ALMS
3
Alumis Inc
ALMS
$2.9B
$37.6M 16.23%
+2,826,048
New +$37.6M
HRMY icon
4
Harmony Biosciences
HRMY
$2.28B
$31.2M 13.49%
1,035,396
– –
SLRN
5
DELISTED
ACELYRIN
SLRN
$17M 7.34%
3,852,470
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$6.57M 2.84%
2,434,255
-261,878
-10% -$986K

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q2 2024 Portfolio in Review

As of Q2 2024, venBio Partners held 6 positions worth $232M, down 18% from $282M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $36.6M of net new capital in Q2 2024, opening 1 new position. Its largest new stake was Alumis Inc: 2,826,048 shares worth $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Elevation Oncology, an estimated $986K trimmed.

  • venBio Partners's largest Q2 2024 buy was Alumis Inc: 2,826,048 shares worth $37.6M.
  • venBio Partners's biggest Q2 2024 reduction was Elevation Oncology, cutting an estimated $986K.
  • venBio Partners's ten largest holdings make up 100% of its $232M portfolio in Q2 2024.
  • venBio Partners opened 1 new position and closed 0 in Q2 2024.
  • venBio Partners's portfolio value fell 18% quarter-over-quarter to $232M.

Based on venBio Partners's 13F filing for Q2 2024, filed 14 Aug 2024.